In a move designed to bridge the gap between ho-hum upstream research and the rarefied world of clinical genotyping and diagnostics, Genaissance Pharmaceuticals has decided to buy all of the genotyping technologies and lab-based diagnostic products made by DNA Sciences.

The $1.3 million acquisition, announced in concert with DNA Sciences’ decision to seek Chapter 11 bankruptcy protection, makes Genaissance the first pharmacogenomics company to offer high-throughput haplotyping services along with a modest suite of commercialized CLIA- and GLP-rated tests.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

In Nature this week: a Danish reference genome, and more.